Shield Diagnostics shares soar
Shares in Shield Diagnostics soared 30p to 552.5p after the group reported positive comments on its diagnostic test for heart disease, Associated Factor Twelve, from a Florence conference of cardiologists and haematologists.
The company said that the reception at the conference would help in in ongoing collaborative talks with potential partners for the test, which could be an alternative to cholesterol testing. Earlier this year, shares in the group soared following leaks that the AFT test was a better predictor of heart attacks than the traditional cholesterol test. Shield said yesterday that it could confirm that collaborative talks were pro gressing satisfactorily as were the group's plans to commercialise AFT.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies